REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH): Nasdaq/NYSE listing notice — Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Nasdaq Hearings Panel determined to delist RVPH due to non-compliance with minimum $1.00 bid price rule.
Trading on Nasdaq suspended as of May 14, 2026; stock will quote on OTCQB Venture Market under same symbol RVPH.
Delisting risks include reduced liquidity, fewer investors, penny stock classification, and limited analyst coverage.
Company updated risk factors to reflect additional risks of OTC trading vs. national exchange listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-016538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.